{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:35:40Z","timestamp":1694633740943},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.juro.2008.06.070","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T08:52:19Z","timestamp":1216371139000},"page":"811-812","source":"Crossref","is-referenced-by-count":4,"title":["How Many Drugs for LUTS Due to BPH are Too Many?"],"prefix":"10.1097","volume":"180","author":[{"given":"Karl-Erik","family":"Andersson","sequence":"first","affiliation":[{"name":"Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2008.06.070_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2008.06.070_bib2","series-title":"Male Lower Urinary Tract Dysfunction","first-page":"143","article-title":"New medical developments in the management of LUTS in adult men. World Health Organisation Report\u2014Committee 6","author":"Chapple","year":"2006"},{"key":"10.1016\/j.juro.2008.06.070_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00345-006-0092-0","article-title":"First-line treatment for symptomatic benign prostatic hyperplasia: is there a particular patient profile for a particular treatment?","volume":"24","author":"Gonzalez","year":"2006","journal-title":"World J Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib4","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.juro.2006.06.022","article-title":"Prevention of benign prostatic hyperplasia disease","volume":"176","author":"Marks","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib5","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/nau.20500","article-title":"LUTS treatment: future treatment options","volume":"26","author":"Andersson","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.juro.2008.06.070_bib6","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.juro.2008.06.070_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0090-4295(01)01201-8","article-title":"Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia","volume":"58","author":"Baldwin","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.juro.2008.06.070_bib8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0302-2838(03)00367-1","article-title":"Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride","volume":"44","author":"Barkin","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib9","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.juro.2008.06.070_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00029330-200703010-00004","article-title":"Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study","volume":"120","author":"Yang","year":"2007","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.juro.2008.06.070_bib11","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","article-title":"Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib12","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","article-title":"Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.eururo.2008.01.075","article-title":"A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"53","author":"Stief","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib14","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","article-title":"Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"51","author":"Kaplan","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2008.06.070_bib15","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/01.ju.0000142687.75577.e4","article-title":"Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men","volume":"172","author":"Kloner","year":"2004","journal-title":"J Urol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534708016996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0022534708016996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2008.06.070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:25:09Z","timestamp":1651195509000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2008.06.070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1016\/j.juro.2008.06.070"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2008.06.070","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}